Q4 2025 · 13F-HR
Opaleye Management Inc.holdings as filed
Filed 2026-02-17 · accession 0001493152-26-007085
$758.0M
Reported value
54
Positions
2025-12-31
Period end
The Brief · Opaleye Management Inc. · Q4 2025
AI · grounded in 13F
Opaleye Management Inc. closed its position in IMNM, reducing exposure by $37.3M. The fund established new positions in CBIO for $13.97M and KPTI for $6.84M. Additionally, the manager increased its stake in ACOG by 1698.46% and SLGL by 121.51%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 415858109 | HROW | HARROW HEALTH INC | $191.3M | 25.2% | 3,905,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $85.0M | 11.2% | 2,435,000 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $48.4M | 6.38% | 2,860,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $35.3M | 4.66% | 330,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $29.3M | 3.87% | 388,257 | Common | SOLE |
| 80303D305 | SNWV | SANUWAVE HEALTH INC | $29.3M | 3.86% | 981,267 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $22.1M | 2.91% | 695,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $19.4M | 2.55% | 1,595,000 | Common | SOLE |
| M8694L137 | SLGL | SOL GEL TECHNOLOGIES | $19.1M | 2.52% | 453,739 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $17.0M | 2.25% | 410,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $15.9M | 2.10% | 535,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $15.9M | 2.10% | 200,000 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $14.8M | 1.96% | 6,287,156 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC | $14.0M | 1.84% | 1,178,300 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $13.7M | 1.81% | 490,000 | Common | SOLE |
| 02074J501 | ACOG | ALPHA COGNITION INC | $13.5M | 1.78% | 2,070,784 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $13.1M | 1.72% | 2,600,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $12.4M | 1.64% | 500,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $11.1M | 1.46% | 6,789,738 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $9.2M | 1.21% | 105,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $8.4M | 1.11% | 2,720,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $8.2M | 1.08% | 260,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $8.0M | 1.05% | 100,000 | Common | SOLE |
| 98419J206 | XOMA | XOMA CORP DEL | $7.8M | 1.03% | 292,590 | Common | SOLE |
| 48115J109 | DERM | JOURNEY MEDICAL CORP | $7.5M | 0.99% | 975,000 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $6.8M | 0.90% | 930,000 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $6.6M | 0.87% | 427,608 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $6.3M | 0.83% | 268,423 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $5.2M | 0.69% | 535,000 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $5.0M | 0.66% | 1,184,500 | Common | SOLE |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $4.7M | 0.62% | 1,196,904 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $4.5M | 0.60% | 935,000 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTICS INC | $4.5M | 0.59% | 214,747 | Common | SOLE |
| 74365A309 | PLX | PROTALIX BIOTHERAPEUTICS INC | $4.5M | 0.59% | 2,478,176 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $4.3M | 0.57% | 345,100 | Common | SOLE |
| 34960Q307 | FBIO | FORTRESS BIOTECH INC | $4.0M | 0.53% | 1,090,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $3.4M | 0.44% | 955,000 | Common | SOLE |
| G59665102 | MGTX | MEIRAGTX HOLDINGS PLC | $3.1M | 0.41% | 390,844 | Common | SOLE |
| 766559702 | RIGL | RIGEL PHARMACEUTICALS INC | $3.0M | 0.40% | 70,000 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $2.9M | 0.38% | 108,929 | Common | SOLE |
| 04546C205 | ASRT | ASSERTIO HOLDINGS INC | $2.6M | 0.34% | 285,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $2.3M | 0.30% | 251,932 | Common | SOLE |
| 67577R102 | IRD | OPUS GENETICS INC | $2.3M | 0.30% | 1,120,000 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $2.2M | 0.29% | 190,671 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $2.0M | 0.26% | 900,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $1.9M | 0.25% | 1,400,906 | Common | SOLE |
| 37148K209 | — | GENERATION BIO CO | $1.8M | 0.23% | 310,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $1.4M | 0.18% | 18,319 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $1.2M | 0.16% | 75,000 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $708,365 | 0.09% | 213,363 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $641,940 | 0.08% | 179,815 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $479,870 | 0.06% | 78,926 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $213,363 | 0.03% | 150,000 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $114,994 | 0.02% | 110,571 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.